- Home
- JMM vs NRXP Comparison
JMM vs NRXP Comparison
Compare JMM & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMM
- NRXP
- Stock Information
- Founded
- JMM 1988
- NRXP 2015
- Country
- JMM United States
- NRXP United States
- Employees
- JMM N/A
- NRXP N/A
- Industry
- JMM Trusts Except Educational Religious and Charitable
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- JMM Finance
- NRXP Health Care
- Exchange
- JMM Nasdaq
- NRXP Nasdaq
- Market Cap
- JMM 60.4M
- NRXP 58.5M
- IPO Year
- JMM N/A
- NRXP N/A
- Fundamental
- Price
- JMM $6.30
- NRXP $2.69
- Analyst Decision
- JMM
- NRXP Strong Buy
- Analyst Count
- JMM 0
- NRXP 4
- Target Price
- JMM N/A
- NRXP $29.25
- AVG Volume (30 Days)
- JMM 16.1K
- NRXP 398.9K
- Earning Date
- JMM 01-01-0001
- NRXP 08-18-2025
- Dividend Yield
- JMM 5.44%
- NRXP N/A
- EPS Growth
- JMM N/A
- NRXP N/A
- EPS
- JMM N/A
- NRXP N/A
- Revenue
- JMM N/A
- NRXP N/A
- Revenue This Year
- JMM N/A
- NRXP N/A
- Revenue Next Year
- JMM N/A
- NRXP $231.16
- P/E Ratio
- JMM N/A
- NRXP N/A
- Revenue Growth
- JMM N/A
- NRXP N/A
- 52 Week Low
- JMM $5.29
- NRXP $1.10
- 52 Week High
- JMM $6.10
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- JMM 47.83
- NRXP 48.96
- Support Level
- JMM $6.25
- NRXP $2.40
- Resistance Level
- JMM $6.40
- NRXP $2.95
- Average True Range (ATR)
- JMM 0.10
- NRXP 0.22
- MACD
- JMM -0.01
- NRXP 0.03
- Stochastic Oscillator
- JMM 36.00
- NRXP 60.00
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.